MediWound Ltd. reported total revenue of $5.7 million for the second quarter ended June 30, 2025, marking a 43% sequential increase. The company posted a net loss of $13.3 million, or $1.23 per share, significantly impacted by $6.6 million in noncash financial expenses from warrant revaluation.
Gross profit improved to $1.3 million (23.5% of revenue) in Q2 2025, up from $0.4 million (8.8%) in Q2 2024, driven by a favorable revenue mix. However, R&D expenses increased to $3.5 million from $1.9 million in Q2 2024, primarily due to the EscharEx VALUE Phase III study.
As of June 30, 2025, MediWound held $32.9 million in cash, cash equivalents, and short-term deposits. The company used $11.9 million to fund operations in the first half of 2025, including $2.3 million in capital expenditures. Strategic collaborations with Essity and Convatec were established, and NexoBrid manufacturing expansion remains on track for full operational capacity by year-end 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.